Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Innate Immunotherapeutics Ltd launches IPO to raise up to A$12 million


Tuesday, 26 Nov 2013 03:00pm EST 

Innate Immunotherapeutics:Says it launches Initial Public Offer (IPO) to raise up to A$12 million through the offer of up to 60 million shares.Says commitments for A$5 million have been received, including A$3 million from Australian Ethical Smaller Companies Trust who have provided the cornerstone investment for the IPO.Says majority of funds raised will be used to conduct a placebo controlled Phase 2B efficacy trial for its lead drug candidate MIS416 for secondary progressive multiple sclerosis (SPMS).Says Patersons Securities Limited and Morgans Corporate Limited are joint lead managers to the IPO. 

Company Quote

50.03
-0.06 -0.12%
26 Nov 2014